Get started
Author

Mathilda Kovacek

Observed name: M. Kovacek
Institution: BioInvent (Sweden)
Observed institution: BioInvent (Sweden)
ORCID: 0009-0002-5156-7261
Observed ORCID: 0009-0002-5156-7261
OpenAlex ID: A5023906837
Antagonistic Human FcγRIIB (CD32B) Antibodies Have Anti-Tumor Activity and Overcome Resistance to Antibody Therapy In Vivo
2015 · Ali Roghanian, Ingrid Teige, et al. · Cancer Cell · 135
PDF
A Human ICAM-1 Antibody Isolated by a Function-First Approach Has Potent Macrophage-Dependent Antimyeloma Activity In Vivo
2013 · Niina Veitonmäki, Markus Hansson, et al. · Cancer Cell · 73
PDF
A platform for phenotypic discovery of therapeutic antibodies and targets applied on Chronic Lymphocytic Leukemia
2018 · A. Ljungars, L. Mårtensson, et al. · npj Precision Oncology · 16
PDF
Targeting FcγRIIB by antagonistic antibody BI-1206 improves the efficacy of rituximab-based therapies in aggressive mantle cell lymphoma
2022 · Vivian Changying Jiang, Yang Liu, et al. · Journal of Hematology & Oncology · 10
PDF
725 Pre-clinical development of TNFR2 ligand-blocking BI-1808 for cancer immunotherapy
2020 · Linda Mårtensson, Mathilda Kovacek, et al. · Journal for ImmunoTherapy of Cancer · 9
Abstract 936: Targeting TNFR2 for cancer immunotherapy: Ligand blocking depletors versus receptor agonists
2020 · Linda Mårtensson, Kirstie Cleary, et al. · Cancer Research · 9
Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
2026 · Linda Mårtensson, Petra Holmkvist, et al. · Cancer Research · 3
Abstract 4156: BI-1808 - a first in class ligand-blocking αTNFR2 antibody for cancer immunotherapy
2022 · Linda Mårtensson, Kirsty Cleary, et al. · Cancer Research · 3
1368 Preclinical development of an agonistic anti-TNFR2 antibody (BI-1910) for cancer immunotherapy
2023 · Linda Martensson, Petra Holmkvist, et al. · Journal for ImmunoTherapy of Cancer · 2
PDF
Abstract 1642: A novel FcγRIIB-blocking antibody to enhance FcγR-dependent antitumor immunity
2021 · Linda Mårtensson, Robert Oldham, et al. · Cancer Research · 1
Targeting Antibody Checkpoint Fcgriib Using Monoclonal Antibody BI-1206 to Overcome Therapeutic Resistance in Mantle Cell Lymphoma
2020 · Alexa A Jordan, Joseph McIntosh, et al. · Blood · 1
BI-1206, a Monoclonal Antibody Against Fcγriib, Showed Superior Anti-Tumor Activity in an Ibrutinib-Venetoclax Dual Resistant PDX Model in Mantle Cell Lymphoma
2019 · Changying Jiang, Yang Liu, et al. · Blood · 1
Supplementary Fig 1 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
2026 · Linda Mårtensson, Petra Holmkvist, et al.
Supplementary Fig 5 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
2026 · Linda Mårtensson, Petra Holmkvist, et al.
Supplementary Fig 4 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
2026 · Linda Mårtensson, Petra Holmkvist, et al.
Supplementary Table 1 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
2026 · Linda Mårtensson, Petra Holmkvist, et al.
Data from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
2026 · Linda Mårtensson, Petra Holmkvist, et al.
Supplementary Fig 3 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
2026 · Linda Mårtensson, Petra Holmkvist, et al.
Supplementary Fig 10 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
2026 · Linda Mårtensson, Petra Holmkvist, et al.
Supplementary Fig 8 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
2026 · Linda Mårtensson, Petra Holmkvist, et al.
Anti-TNFR2 antibody BI-1808 induces tumor regression and antitumor T cell immunity through T reg and myeloid cell modulation in patients with solid tumors
2026 · Ingrid Teige, Kristoffer S. Rohrberg, et al. · Clinical Cancer Research
Supplementary Fig 9 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
2026 · Linda Mårtensson, Petra Holmkvist, et al.
Supplementary Fig 7 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
2026 · Linda Mårtensson, Petra Holmkvist, et al.
Supplementary Fig 2 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
2026 · Linda Mårtensson, Petra Holmkvist, et al.
Supplementary Fig 6 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
2026 · Linda Mårtensson, Petra Holmkvist, et al.
Works count: 28
Citation count: 263
H-index: 6
I10-index: 4
Year
Topic
Type